NASDAQ : PEPG

PepGen Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 2.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 166.92M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Details

NamePepGen Inc.
SectorHealthcare
IndustryBiotechnology
Employees57
Founded2018
Ipo Date2022-05-06
CeoJames McArthur
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price12.00
IsinUS7133171055
Cusip713317105
Cik1835597
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. James G. McArthur Ph.D.President, Chief Executive Officer, Treasurer, Secretary and Director
Noel P. Donnelly M.B.A.Chief Financial Officer
Joseph D. Vittiglio Esq., J.D.Chief Business and Legal Officer and Secretary
Dr. Kasra Kasraian Ph.D.Chief Technical Officer
Emiko BryantSenior Vice President of Human Resources and Administration
Dr. Hayley Parker Ph.D.Senior Vice President of Global Regulatory Affairs and Quality
Dr. Paul D. Streck M.B.A., M.D.Executive Vice President and Head of Research and Development
Pallavi Lonkar Ph.D.Vice President and Head of Preclinical
Melissa MichaelsExecutive Director and Head of Regulatory Affairs CMC
Michael ZhaoVice President and Head of Biometrics

Contact

Address321 Harrison Avenue, 8th Floor, Boston, Massachusetts 02118, United States
Phone781 797 0979
Websitehttps://www.pepgen.com